Supporting information for

Enhanced *In Vivo* Antitumor Efficacy of Doxorubicin Encapsulated within Laponite Nanodisks

Kai Li,[a,1] Shige Wang,[b,1] Shihui Wen,[c] Yueqin Tang,[d] Jipeng Li,[a] Xiangyang Shi,[b,c] and Qinghua Zhao[a*]*

[a] Department of orthopaedics, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.

[b] State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Donghua University, Shanghai 201620, China.

[c] College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.

[d] Experiment Center, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China.

Table S1. Blood routine parameters of mice at days 7 and 14 post treatment with saline, LAP, LAP/DOX, and free DOX.

	Hb (g/L)		WBC ($\times 10^9$/L)		PLT ($\times 10^{12}$/L)	
	d 7	d 14	d 7	d 14	d 7	d 14
Saline	145	131	4.98	4.62	1.28	1.30
LAP	142	131	4.23	4.23	1.25	1.25
LAP/DOX	136	132	4.17	4.30	1.23	1.23
DOX	133	115	2.71	1.92	1.17	0.42

Table S2. Serum biochemistry parameters of mice at days 7 and 14 post treatment with saline, LAP, LAP/DOX, and free DOX.

	AST (U/L)		ALT(U/L)		Total Bilirubin (umol/L)		Creatinine (umol/L)		Carbamide (umol/L)	
	d 7	d 14	d 7	d 14	d 7	d 14	d 7	d 14	d 7	d 14
Saline	111	105	35	39	5.7	5.6	18	17	7.8	7.8
LAP	117	102	29	29	5.9	5.9	13	10	7.1	7.3
LAP/DOX	113	112	33	35	5.9	5.9	20	18	6.6	6.5
DOX	139	159	50	63	9.2	9.9	22	28	6.8	9.1



Figure S1. FTIR spectra of LAP and LAP/DOX nanodisks.



Figure S2. (a) Representative photos of KB tumor bearing mice before treatment (noted as day 0). (b) HE staining showing the morphology of the KB cancer cells.



Figure S3. Representative photos of KB tumor bearing mice after various treatments at day 1 and day 19.



Figure S4. Body weight curves of KB tumor bearing mice after treatments with saline, free DOX, and LAP/DOX complexes (Mean ± SD, n = 6).